Abstract
Bioactive food components (BFACs) represent promising candidates for liver cancer chemoprevention. Among them, isoprenic derivatives (carotenoids, retinoids, perillyl alcohol, limonene, geraniol, farnesol, geranylgeraniol and β- ionone) can be highlighted. The relevance of animal models for the investigation of chemopreventive agents is supported by comparative functional genomic studies that reinforce the similarities between rodent and human hepatocarcinogenesis. Thus, characterization of BFACs in animal models as blocking and/or suppressing agents allows the establishment of the theoretical basis for the development of chemoprevention strategies. Dietary isoprenic derivatives actions on hepatocarcinogenesis may involve a block in carcinogen activation, induction of phase 2 enzymes and an antioxidant activity, as well as interference with cellular processes including cell communication, proliferation, apoptosis, differentiation and remodeling of preneoplastic lesions. Dietary isoprenic derivatives modulate molecular targets including HMG-CoA-reductase, Rho, nuclear receptors, c-myc, connexin 43, NF-κB and Nrf2. Several networks related to these targets are altered in early phases of hepatocarcinogenesis. This emphasizes the importance of such agents for the chemoprevention of hepatocellular carcinoma. Combinations of isoprenic derivatives or of these substances with other BFACs classes should be further investigated. Also, toxicity and bioavailability and pharmacokinetic aspects of these derivatives represent relevant issues in their development as chemopreventive agents. One major current limitation of the adoption of dietary isoprenic derivatives for liver cancer chemoprevention is the challenge in overcoming the initial preclinical phase in agent development. Dietary isoprenic derivatives that present liver cancer chemopreventive properties should be further explored in clinical trials, begining with the phase 0 approach.
Keywords: Bioactive food components, cellular targets, chemoprevention, dietary isoprenic derivatives, liver cancer, molecular targets, retinoid X receptors, retinoic acid receptors, resistant hepatocyte, preneoplastic lesions, nonalcoholic steatohepatitis, diethylnitrosamine, farnesoid X receptor, gamma glutamyl transpeptidase, hepatocellular carcinoma
Current Cancer Drug Targets
Title:Chemoprevention of Hepatocarcinogenesis with Dietary Isoprenic Derivatives: Cellular and Molecular Aspects
Volume: 12 Issue: 9
Author(s): Thomas Prates Ong, Monica Testoni Cardozo, Aline de Conti and Fernando Salvador Moreno
Affiliation:
Keywords: Bioactive food components, cellular targets, chemoprevention, dietary isoprenic derivatives, liver cancer, molecular targets, retinoid X receptors, retinoic acid receptors, resistant hepatocyte, preneoplastic lesions, nonalcoholic steatohepatitis, diethylnitrosamine, farnesoid X receptor, gamma glutamyl transpeptidase, hepatocellular carcinoma
Abstract: Bioactive food components (BFACs) represent promising candidates for liver cancer chemoprevention. Among them, isoprenic derivatives (carotenoids, retinoids, perillyl alcohol, limonene, geraniol, farnesol, geranylgeraniol and β- ionone) can be highlighted. The relevance of animal models for the investigation of chemopreventive agents is supported by comparative functional genomic studies that reinforce the similarities between rodent and human hepatocarcinogenesis. Thus, characterization of BFACs in animal models as blocking and/or suppressing agents allows the establishment of the theoretical basis for the development of chemoprevention strategies. Dietary isoprenic derivatives actions on hepatocarcinogenesis may involve a block in carcinogen activation, induction of phase 2 enzymes and an antioxidant activity, as well as interference with cellular processes including cell communication, proliferation, apoptosis, differentiation and remodeling of preneoplastic lesions. Dietary isoprenic derivatives modulate molecular targets including HMG-CoA-reductase, Rho, nuclear receptors, c-myc, connexin 43, NF-κB and Nrf2. Several networks related to these targets are altered in early phases of hepatocarcinogenesis. This emphasizes the importance of such agents for the chemoprevention of hepatocellular carcinoma. Combinations of isoprenic derivatives or of these substances with other BFACs classes should be further investigated. Also, toxicity and bioavailability and pharmacokinetic aspects of these derivatives represent relevant issues in their development as chemopreventive agents. One major current limitation of the adoption of dietary isoprenic derivatives for liver cancer chemoprevention is the challenge in overcoming the initial preclinical phase in agent development. Dietary isoprenic derivatives that present liver cancer chemopreventive properties should be further explored in clinical trials, begining with the phase 0 approach.
Export Options
About this article
Cite this article as:
Prates Ong Thomas, Testoni Cardozo Monica, de Conti Aline and Salvador Moreno Fernando, Chemoprevention of Hepatocarcinogenesis with Dietary Isoprenic Derivatives: Cellular and Molecular Aspects, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091173
DOI https://dx.doi.org/10.2174/15680096112091173 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Pathogenesis of Non Muscle-Invasive Bladder Cancer: Implications for Novel Targeted Therapies
Current Molecular Medicine The Effects of Bisphosphonates on the Bone Marrow Niche and Circulating and Disseminated Tumor Cells
Current Cancer Therapy Reviews Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Apoptosis in Obstructive Nephropathy
Current Pediatric Reviews Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Melanoma Skin Cancer Detection based on Image Processing
Current Medical Imaging Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design SUBJECT INDEX TO VOLUME 1
Current Genomics Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging 5-Hydroxymethylfurfural (HMF) in Organic Synthesis: A Review of its Recent Applications Towards Fine Chemicals
Current Organic Synthesis Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science Editorial (Thematic Issue: Signal Transduction of Natural Products for Anticancer Therapy)
Current Signal Transduction Therapy New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Fluorinated Mechanism-Based Inhibitors: Common Themes and Recent Developments
Current Topics in Medicinal Chemistry Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Editorial (Thematic Issue: Systems and Network Biology in Pharmaceutical Drug Discovery)
Current Pharmaceutical Design How Does Plasma Activated Media Treatment Differ From Direct Cold Plasma Treatment?
Anti-Cancer Agents in Medicinal Chemistry Cytoskeleton-Anchoring of Conformational Mutant-Like p53, but Not Shorter Isoforms p53β and p47 (ΔN40p53) in Senescent Human Fibroblasts
Current Aging Science